The Beginning of a New Era: Where Are We Going with Immunotherapies in Resectable NSCLC? - European Medical Journal

Continue

The Beginning of a New Era: Where Are We Going with Immunotherapies in Resectable NSCLC?

Oncology

At the European Society for Thoracic Surgeons (ESTS) 2023 Conference, Erin Gillaspie, Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and Francesco Grossi, Medical Oncology Division, University of Insubria, Varese, Italy, shared their perspectives on the future of immunotherapies and practical considerations in resectable non-small cell lung cancer (NSCLC) using a patient case.

This symposium was developed and funded by the medical department of Bristol Myers Squibb.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given